Capivasertib treatment associated with hypermetabolism of the spleen

Maria Ly; Gary Z. Yu; Amin Haghighat Jahromi

doi:10.1186/s41824-024-00231-7

Capivasertib treatment associated with hypermetabolism of the spleen

Maria Ly
, Gary Z. Yu
, Amin Haghighat Jahromi

Research output: Contribution to journal › Article › peer-review

Abstract

Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.

Original language	English
Article number	10
Journal	EJNMMI Reports
Volume	9
Issue number	1
DOIs	https://doi.org/10.1186/s41824-024-00231-7
State	Published - Dec 2025

Keywords

Capivasertib
Side effect
Splenic hypermetabolism
[18F]-FDG PET/CT

Access to Document

10.1186/s41824-024-00231-7

Cite this

@article{b3e674ba6f84440ba1a89c4669ca84d1,

title = "Capivasertib treatment associated with hypermetabolism of the spleen",

abstract = "Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.",

keywords = "Capivasertib, Side effect, Splenic hypermetabolism, [18F]-FDG PET/CT",

author = "Maria Ly and Yu, \{Gary Z.\} and Jahromi, \{Amin Haghighat\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2025",

month = dec,

doi = "10.1186/s41824-024-00231-7",

language = "English",

volume = "9",

journal = "EJNMMI Reports",

issn = "3005-074X",

number = "1",

}

TY - JOUR

T1 - Capivasertib treatment associated with hypermetabolism of the spleen

AU - Ly, Maria

AU - Yu, Gary Z.

AU - Jahromi, Amin Haghighat

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2025/12

Y1 - 2025/12

N2 - Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.

AB - Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.

KW - Capivasertib

KW - Side effect

KW - Splenic hypermetabolism

KW - [18F]-FDG PET/CT

UR - https://www.scopus.com/pages/publications/105000805683

U2 - 10.1186/s41824-024-00231-7

DO - 10.1186/s41824-024-00231-7

M3 - Article

C2 - 40122972

AN - SCOPUS:105000805683

SN - 3005-074X

VL - 9

JO - EJNMMI Reports

JF - EJNMMI Reports

IS - 1

M1 - 10

ER -

Capivasertib treatment associated with hypermetabolism of the spleen

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this